U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07550595) titled 'Oritavancin for Treatment of Serious Cardiac Infections' on March 26.
Brief Summary: Cardiac infections, including infective endocarditis and cardiovascular implantable electronic device infections, are associated with substantial morbidity and mortality and are commonly caused by gram-positive bacteria. Standard management typically requires prolonged courses of intravenous antibiotics and extended hospitalisation, which are costly, burdensome, and associated with complications related to long-term vascular access. People who inject drugs are disproportionately affected and often experience stigma, barriers to care, and poorer out...